Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Clinical trial NCT04987112 · UNKNOWN

Trial details

NCT number: NCT04987112
Sponsor: CanWell Pharma Inc.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Cancer Metastatic

Start date: 2022-01-20
Primary completion: 2024-12-30
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.